GcMAF and/or oral MAF immunotherapy are recommended for the management of conditions characterized by immune dysfunction or compromised immune systems, including but not limited to:
| Cancer | Autoimmune diseases | Respiratory tract infections |
| Autism Spectrum Disorders (ASD) | Herpes Simplex virus (HSV) | Epstein-Barr Virus (EBV) |
| Chronic Fatigue Syndrome (CFS) | Multiple sclerosis (MS) | Cystitis |
| Myalgic Encephalomyelitis (ME) | Rheumatoid arthritis (RA) | Urinary tract infection (UTI) |
| Tuberculosis | Lyme disease (Lyme borreliosis) | Endometriosis |
| Lupus (Systemic lupus erythematosus, SLE) | Mycobacteria infections | Parkinson’s disease |
| Pneumonia infection | Fibromyalgia | Norovirus |
| Malaria | Warts caused by viral infection | Herpes simplex virus (HSV) |
| Q fever (Coxiella burnetii) | Influenza virus (flu) | Chicken pox (varicella zoster virus) |
| Psoriasis | Polycystic ovary syndrome (PCOS) | Ulcerative colitis, Crohn’s disease |